Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Pegram

Showing results (11-20 of 66) with videos related to

Pageof 7
Sort By:
Seminars in Oncology|August 8, 2006
Targeting HER2 EpitopesSumanta Kumar Pal, Mark Pegram
Breast Cancer Research and Treatment|October 2, 2009
Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancerSumanta K Pal, Barrett H Childs, Mark Pegram
Breast Cancer Research and Treatment|December 17, 2010
Triple negative breast cancer: unmet medical needsSumanta Kumar Pal, Barrett H Childs, Mark Pegram
Breast Cancer (Dove Medical Press)|December 25, 2013
Lapatinib: new opportunities for management of breast cancerJulia Liao, Michelle Gallas, Mark Pegram, et al.
NPJ Breast Cancer|May 31, 2023
Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancerMark Pegram, Christian Jackisch, Stephen R D Johnston
Clinical Breast Cancer|September 10, 2008
Expert roundtable: emerging questions in ErbB2-positive breast cancer; February 22, 2007Mark Pegram, Edith A Perez, Martine Piccart, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 27, 2016
Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancerJunjun Liu, Xiaosong Chen, Toby Ward, et al.
Breast Cancer (Tokyo, Japan)|August 25, 2011
Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancerKazuhiro Araki, Shigehira Saji, Michelle Gallas, et al.
Future Oncology (London, England)|June 30, 2021
Biosimilars in an era of rising oncology treatment optionsMarc Peeters, David Planchard, Mark Pegram, et al.
Anti-Cancer Drugs|March 27, 2002
Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011Christopher R Boyer, Patricia L Karjian, Geoffrey M Wahl, et al.
Pageof 7

Showing results (11-20 of 66) with videos related to

Sort By:
Pageof 7
Seminars in Oncology|August 8, 2006
Targeting HER2 EpitopesSumanta Kumar Pal, Mark Pegram
Breast Cancer Research and Treatment|October 2, 2009
Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancerSumanta K Pal, Barrett H Childs, Mark Pegram
Breast Cancer Research and Treatment|December 17, 2010
Triple negative breast cancer: unmet medical needsSumanta Kumar Pal, Barrett H Childs, Mark Pegram
Breast Cancer (Dove Medical Press)|December 25, 2013
Lapatinib: new opportunities for management of breast cancerJulia Liao, Michelle Gallas, Mark Pegram, et al.
NPJ Breast Cancer|May 31, 2023
Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancerMark Pegram, Christian Jackisch, Stephen R D Johnston
Clinical Breast Cancer|September 10, 2008
Expert roundtable: emerging questions in ErbB2-positive breast cancer; February 22, 2007Mark Pegram, Edith A Perez, Martine Piccart, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 27, 2016
Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancerJunjun Liu, Xiaosong Chen, Toby Ward, et al.
Breast Cancer (Tokyo, Japan)|August 25, 2011
Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancerKazuhiro Araki, Shigehira Saji, Michelle Gallas, et al.
Future Oncology (London, England)|June 30, 2021
Biosimilars in an era of rising oncology treatment optionsMarc Peeters, David Planchard, Mark Pegram, et al.
Anti-Cancer Drugs|March 27, 2002
Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011Christopher R Boyer, Patricia L Karjian, Geoffrey M Wahl, et al.
Pageof 7